Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shiva Malek

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Disease Models & Mechanisms|September 9, 2021
Biology, technology and a bit of serendipity: an interview with Shiva MalekShiva Malek
Molecular Cell|January 18, 2020
Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting TumorigenesisAvinashnarayan Venkatanarayan, Shiva Malek
Cold Spring Harbor Perspectives in Medicine|February 15, 2018
Targeting the MAPK Pathway in RAS Mutant CancersSarah G Hymowitz, Shiva Malek
Molecular Cell|December 3, 2016
The RAS/MAPK Axis Gets Stressed OutScott A Foster, Shiva Malek
Cancer Cell|August 10, 2021
The promise and peril of KRAS G12C inhibitorsAmanda R Moore, Shiva Malek
Cancer Discovery|April 3, 2021
Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming ResistanceJoachim Rudolph, Jeff Settleman, Shiva Malek
Trends in Cancer|July 26, 2017
Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic ApproachesScott A Foster, Christiaan Klijn, Shiva Malek
Cell Death & Disease|March 4, 2020
The 9th Barossa Meeting: Cell Signalling in Cancer MedicineLoretta Dorstyn, Denis Tvorogov, Shiva Malek, et al.
Nature Reviews. Drug Discovery|June 13, 2020
RAS-targeted therapies: is the undruggable drugged?Amanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Nature Reviews. Drug Discovery|May 15, 2021
RAS-targeted therapiesAmanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Disease Models & Mechanisms|September 9, 2021
Biology, technology and a bit of serendipity: an interview with Shiva MalekShiva Malek
Molecular Cell|January 18, 2020
Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting TumorigenesisAvinashnarayan Venkatanarayan, Shiva Malek
Cold Spring Harbor Perspectives in Medicine|February 15, 2018
Targeting the MAPK Pathway in RAS Mutant CancersSarah G Hymowitz, Shiva Malek
Molecular Cell|December 3, 2016
The RAS/MAPK Axis Gets Stressed OutScott A Foster, Shiva Malek
Cancer Cell|August 10, 2021
The promise and peril of KRAS G12C inhibitorsAmanda R Moore, Shiva Malek
Cancer Discovery|April 3, 2021
Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming ResistanceJoachim Rudolph, Jeff Settleman, Shiva Malek
Trends in Cancer|July 26, 2017
Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic ApproachesScott A Foster, Christiaan Klijn, Shiva Malek
Cell Death & Disease|March 4, 2020
The 9th Barossa Meeting: Cell Signalling in Cancer MedicineLoretta Dorstyn, Denis Tvorogov, Shiva Malek, et al.
Nature Reviews. Drug Discovery|June 13, 2020
RAS-targeted therapies: is the undruggable drugged?Amanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Nature Reviews. Drug Discovery|May 15, 2021
RAS-targeted therapiesAmanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Pageof 6